Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 12
    records per page




    Increased prolonged sitting in rheumatoid arthritis HP rheumatoid arthritis MESHD patients during the COVID-19 pandemic: a within-subjects, accelerometer-based study

    Authors: Ana Jessica Pinto; Diego Rezende; Sofia Mendes Sieczkowska; Kamila Meireles; Karina Bonfiglioli; Ana C M Ribeiro; Eloisa Bonfa; Neville Owen; David W Dunstan; Hamilton Roschel; Bruno Gualano; Flora A Gandolfi; Stefanie P Murano; Jose L Proenca-Modena; Fernando A Val; Gisely C Melo; Wuelton M Monteiro; Mauricio L Nogueira; Marcus VG Lacerda; Pedro M Moraes-Vieira; Helder I Nakaya; Qiao Wang; Hongbin Ji; Youhua Xie; Yihua Sun; Lu Lu; Yunjiao Zhou

    doi:10.1101/2020.09.09.20191395 Date: 2020-09-11 Source: medRxiv

    Background: Social distancing measures designed to contain the COVID-19 pandemic can explicitly and implicitly restrict physical activity, a particular concern for high-risk patient groups. Using a within-subjects design with objective measurement (via validated accelerometers), we assessed rheumatoid arthritis HP rheumatoid arthritis MESHD patients' physical activity and sedentary behavior levels prior to and during the social distancing measures implemented in Sao Paulo, Brazil. Methods: Post-menopausal women diagnosed with rheumatoid arthritis HP rheumatoid arthritis MESHD were assessed before (from March 2018 to March 2020) and during (from 24th May to 7th July 2020) social distancing measures to contain COVID-19 pandemic, using a within-subjects, repeated-measure design. Physical activity and sedentary behavior were assessed using postural-based accelerometry (ActivPAL micro). Findings: Mean age TRANS was 60.9 years (95%CI: 58.0, 63.7) and BMI was 29.5 Kg/m2 (95%CI: 27.2, 31.9). Disease activity ranged from remission to moderate activity. Most of the patients were using disease-modifying anti-rheumatic drugs and prednisone. Hypertension HP Hypertension MESHD and dyslipidemia MESHD were the most frequent comorbidities During social distancing, there were reductions in total stepping time (15.7% [-0.3 h/day, 95%CI: -0.4, -0.1; p=0.004]), in light-intensity activity (13.0% [-0.2 h/day, 95%CI: -0.4, -0.04; p=0.016]) and in moderate-to-vigorous physical activity (38.8% [-4.5 min/day, 95%CI: -8.1, -0.9; p=0.015]), but no changes in total standing time or total sedentary time. However, time spent in prolonged bouts of sitting <30 min increased by 34% (1.0 h/day, 95%CI: 0.3, 1.7; p=0.006) and sitting bouts <60 min increased by 85% (1.0 h/day, 95%CI: 0.5, 1.6) Sit-stand transitions were reduced by 10% (-5.1/day, 95%CI: -10.3, 0.0; p=0.051). Conclusion: Imposed social distancing measures to contain the COVID-19 outbreak were associated with decreased physical activity and increased prolonged sitting among rheumatoid arthritis HP rheumatoid arthritis MESHD patients. Since this has the potential to increase the burden of cardiovascular disease MESHD in such high-risk patients, attention to maintaining physical activity is an urgent consideration during the pandemic.

    Altered Lipid Profile is a Risk Factor for the Progression Andrecurrenceof COVID-19: From Two Retrospective Cohorts

    Authors: Hui Jin; Junji He; Chuan Dong; Luhong Cao; Xing Qi; Tiande Huang; Zhiyue Ma; Qingjia Gu; Gang He; Jiangang Fan; Bin Li; Xiao long Zhao

    doi:10.21203/rs.3.rs-60159/v1 Date: 2020-08-15 Source: ResearchSquare

    Background The COVID-19 pandemic has spread worldwide. However, the impact of lipid profile and lipid-lowering treatment on clinical endpoints in COVID-19 have not previously been investigated. Methods In this retrospective, multicenter cohort study, we consecutively enrolled 430 adult TRANS COVID-19 patients from two Chinese hospitals (one each in Chengdu and Wuhan) admitted during February 2020 and followed-up until April 30. Demographic, metabolic profile, laboratory, treatment and clinical endpoint data including in-hospital death MESHD and recurrence of COVID-19, were collected. Results In Chengdu patients, univariable and multivariable Cox regression showed that the low-density lipoprotein cholesterol (LDL-C) dyslipidemia MESHD on admission was associated with the recurrence of COVID-19 during the follow-up period. In Wuhan cohort, the patients with triglycerides hyperlipemia MESHD had an increased risk of in-hospital death. However, in both cohorts, statin therapy during COVID-19 course did not affect these clinical endpoints. Compared to the Chengdu cohort, the Wuhan patients tended to have more severe COVID-19 but, unexpectedly, had lower levels of serum SERO lipid. It is of interesting to notice that the relationship between the observed biomarkers of inflammation MESHD and lipid do not match the relationship between the organ function measures and this lipid. Conclusions The baseline dyslipidemia MESHD should be considered as a risk factor for poor prognosis and recurrence of COVID-19. The lipid level may be altered during COVID-19 course, since lipidology may be distinctly affected by both inflammation and organic damage for SARS-CoV-2 MESHD. Further investigation is needed on the role of use of lipid-lowering therapy among patients with COVID-19 infections.

    A Preliminary Study on Blood SERO Lipid Profile in Patients with COVID-19

    Authors: Zhe Zhu; Yayun Yang; Lingyan Fan; Shuyuan Ye; Kehong Lou; Xin Hua; Zuoan Huang; Qiaoyun Shi; Guosheng Gao

    doi:10.21203/rs.3.rs-57301/v1 Date: 2020-08-11 Source: ResearchSquare

    Background: Recently, dyslipidemia MESHD was observed in the patients with coronavirus disease MESHD 2019 (COVID-19). This study aimed to investigate the blood SERO lipid profile in the patients with COVID-19, and explore their predictive value for COVID-19 severity.Methods: 142 consecutive patients with COVID-19 admitted to HwaMei Hospital, University of Chinese Academy of Sciences, from January 23 to April 20, 2020, and 77 age TRANS- and gender TRANS-matched healthy subjects were included in this retrospective study. The blood SERO lipid profile in the patients with COVID-19 were investigated, and their predictive values for COVID-19 severity were analysed.Results: There were 125 and 17 cases in the non-severe and severe group, respectively. Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein A1 (ApoA1) gradually decreased across healthy controls, non-severe group, and severe group. ApoA1 was recognized as an independent risk factor for COVID-19 severity,and had the highest area under the receiver operator characteristic curve (AUC) among all the single markers (AUC: 0.896, 95% CI: 0.834-0.941). Moreover, the risk model established using ApoA1 and IL-6 enhanced the prediction efficiency (AUC: 0.977, 95% CI: 0.932-0.995). Conclusion: The blood SERO lipid profile in the patients with COVID-19 is quite abnormal from healthy subjects, especially in the severe cases. Serum SERO ApoA1 might serve as a good indictor to reflect the severity of COVID-19.

    Safety and Efficacy Concerns of Lopinavir/Ritonavir in COVID-19 Affected Patients: A Retrospective Series

    Authors: Marc-Antoine Lepage; Nicholas Rozza; Richard Kremer; Ami Grunbaum

    doi:10.1101/2020.07.23.20153932 Date: 2020-07-27 Source: medRxiv

    Context: Originally developed for the treatment of human immunodeficiency virus MESHD immunodeficiency HP virus ( HIV MESHD), the antiviral combination lopinavir/ritonavir (LPV/r) is being investigated for use against coronavirus disease (COVID-19). We present a case series raising safety and efficacy concerns in COVID-19 affected patients. Methods: We measured LPV trough concentrations in 12 patients treated at our center and reviewed their clinical charts for side effects known to occur in HIV MESHD patients. Results: Compared to established LPV trough concentrations in HIV MESHD treated patients, concentrations in COVID-19 affected patients were 3-fold greater (20.64 +/- 10.14 mcg/mL versus 6.25 mcg/mL). In addition, cholestasis HP cholestasis MESHD and dyslipidemia toxicity MESHD thresholds were exceeded in 12/12 and 11/12 patients respectively. No patients achieved the presumed therapeutic concentration. The side effects noted were mainly gastrointestinal symptoms (5/12, 42%), electrolytes imbalances (4/12, 33%), liver enzyme disturbances MESHD (5/12, 42%), and triglyceride elevations (2/12, 17%). Conclusion: None of our patients reached presumed therapeutic LPV concentrations despite experiencing side effects and exceeding cholestasis HP cholestasis MESHD and dyslipidemia toxicity MESHD thresholds. This raises concerns for the safety and efficacy of LPV/r. Clinicians should consider closely monitoring for side effects and not necessarily attribute them to COVID-19 itself.

    The Outcome of COVID-19 Patients with Acute Myocardial Infarction MESHD Myocardial Infarction HP

    Authors: Hassan Altamimi; Yasser Alahmad; Fadi Khazal; Mowahib Elhassan; Hajar AlBinali; Abdulrahman Arabi; Awad AlQahtani; Nidal Asaad; Mohammed Al-Hijji; Tahir Hamid; Ihsan Rafie; Ali S. Omrani; Saad AlKaabi; Abdullatif Alkhal; Muna AlMalslmani; Mohammed Ali; Murad Alkhani; Mariam AlNesf; Salem Abu Jalala; Salaheddine Arafa; Reem ElSousy; Omar AlTamimi; Ezzeldine Soaly; Charbel Abi khalil; Jassim Al Suwaidi

    doi:10.1101/2020.07.21.20156349 Date: 2020-07-27 Source: medRxiv

    Background Coronavirus Disease MESHD 2019 (COVID-19) is a rapidly expanding global pandemic resulting in significant morbidity and mortality. COVID-19 patients may present with acute myocardial infarction MESHD myocardial infarction HP ( AMI MESHD). The aim of this study is to conduct detailed analysis on patients with AMI MESHD and COVID-19. Methods We included all patients admitted with AMI MESHD and actively known or found to be COVID-19 positive by PCR between the 4th February 2020 and the 11th June 2020 in the State of Qatar. Patients were divided into ST-elevation myocardial infarction HP myocardial infarction MESHD (STEMI) and Non-STE (NSTEMI). Results There were 68 patients (67 men and 1 woman) admitted between the 4th of February 2020 and the 11th of June 2020 with AMI MESHD and COVID-19. The mean age TRANS was 49.1, 46 patients had STEMI and 22 had NSTEMI. 38% had diabetes mellitus HP diabetes mellitus MESHD, 31% had hypertension HP hypertension MESHD, 16% were smokers, 13% had dyslipidemia MESHD, and 14.7% had prior cardiovascular disease MESHD. Chest pain HP Chest pain MESHD and dyspnea HP dyspnea MESHD were the presenting symptoms in 90% and 12% of patients respectively. Fever HP Fever MESHD (15%) and cough HP cough MESHD (15%) were the most common COVID-19 symptoms, while the majority had no viral symptoms. Thirty-nine (33 STEMI and 6 NSTEMI) patients underwent coronary angiography, 38 of them had significant coronary disease MESHD. Overall in-hospital MACE was low; 1 patient developed stroke HP stroke MESHD and 2 died. Conclusion Contrary to previous small reports, overall in-hospital adverse events were low in this largest cohort of COVID-19 patients presenting with AMI MESHD. We hypothesize patient profile including younger age TRANS contributed to these findings. Further studies are required to confirm this observation.

    The impact of COVID-19 on patients with asthma HP asthma MESHD: A Big Data analysis

    Authors: Jose Luis Izquierdo; Carlos Almonacid; Yolanda Gonzalez; Carlos Del Rio-Bermudez; Julio Ancochea; Remedios Cardenas; Joan B Soriano

    doi:10.1101/2020.07.24.20161596 Date: 2020-07-24 Source: medRxiv

    Background: From the onset of the COVID-19 pandemic, an association between the severity of COVID-19 and the presence of certain medical chronic conditions has been suggested. However, unlike influenza and other viruses, the burden of the disease in patients with asthma HP asthma MESHD has been less evident. Objective: This study aims at a better understanding of the burden of COVID-19 in patients with asthma HP asthma MESHD and the impact of asthma HP, its related comorbidities, and treatment on the prognosis of COVID-19. Methods: We analyzed clinical data from patients with asthma HP asthma MESHD from January 1st to May 10th, 2020 using big data analytics and artificial intelligence through the SAVANA Manager clinical platform. Results: Out of 71,192 patients with asthma HP asthma MESHD, 1,006 (1.41%) suffered from COVID-19. Compared to asthmatic individuals without COVID-19, patients with asthma HP asthma MESHD and COVID-19 were significantly older (55 vs. 42 years), predominantly female TRANS (66% vs. 59%), had higher prevalence SERO of hypertension HP hypertension MESHD, dyslipidemias MESHD, diabetes MESHD, and obesity HP obesity MESHD, and smoked more frequently. Contrarily, allergy HP allergy MESHD-related factors such as rhinitis HP rhinitis MESHD and eczema HP eczema MESHD were less frequent in asthmatic patients with COVID-19 (P < .001). Higher prevalence SERO of hypertension HP hypertension MESHD, dyslipidemia MESHD, diabetes MESHD, and obesity HP obesity MESHD was also confirmed in those patients with asthma HP asthma MESHD and COVID-19 who required hospital admission. The percentage of individuals using inhaled corticosteroids ( ICS MESHD) was lower in patients who required hospitalization due to COVID-19, as compared to non-hospitalized patients (48.3% vs. 61.5%; OR: 0.58: 95% CI 0.44-0.77). During the study period, 865 (1.21%) patients with asthma HP asthma MESHD were being treated with biologics. Although these patients showed increased severity and more comorbidities at the ear, nose, and throat (ENT) level, their hospital admission rates due to COVID-19 were relatively low (0.23%). COVID-19 increased inpatient mortality in asthmatic patients (2.29% vs 0.54%; OR 2.29: 95% CI 4.35-6.66). Conclusion: Our results indicate that the number of COVID-19 cases in patients with asthma HP has been low, although higher than the observed in the general population. Patients with asthma HP asthma MESHD and COVID-19 were older and were at increased risk due to comorbidity-related factors. ICS and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection MESHD.

    Changes in lipid metabolism in patients with severe COVID-19

    Authors: Yi Li; Yan Zhang; Minhui Dai; Minxue Shen; Jianchu Zhang; Yanhui Cui; Ben Liu; Fengyu Lin; Lingli Chen; Duoduo Han; Yifei Fan; Yanjun Zeng; Wen Li; Sha Li; Xiang Chen; Pinhua Pan

    doi:10.21203/rs.3.rs-43521/v1 Date: 2020-07-15 Source: ResearchSquare

    Background: Dyslipidemia MESHD plays an important role in the pathogenesis and evolution of critical illness MESHD, but limited information exists regarding the lipid metabolism of severe coronavirus disease MESHD 2019 (COVID-19) patients. The aim of this study was to investigate role of dyslipidemia MESHD in patients with severe COVID-19Methods: We retrospectively reviewed 216 severe COVID-19 patients with clarified outcomes (discharged or deceased), admitted to the West Court of Union Hospital in Wuhan, China, between February 1 and March 31, 2020. The dynamic changes of lipid profiles and their relationships with disease severity and clinical outcomes were analyzed.Results: A total of 216 severe COVID-19 patients, including 24 non-survivors and 192 survivors, were included in the final analyses. The levels of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein AI (Apo-AI) on admission were significantly lower in non-survivors compared to survivors. During hospitalization, low-density lipoprotein cholesterol (LDL-C), total cholesterol(TC), HDL-C and Apo-AI were shown an increasing trend in survivors, but maintained lower levels or shown downward trend in non-survivors. The serum SERO levels of HDL-C and Apo-AI were inversely correlated with C-reactive protein (CRP), length of hospital stay of survivors and disease severity. The receiver operating characteristic (ROC) curve analysis identified a CRP/ HDL-C ratio cut-off value of 62.54 as the predictor for in-hospital mortality (AUC=0.823, Sensitivity=83.3%, Specificity=70.8%). Logistic regression analysis demonstrated that hypertension HP hypertension MESHD, neutrophils-to-lymphocytes ratio(NLR), platelet count and high CRP/ HDL-C ratio (>62.54) were independent factors to predict in-hospital mortality.Conclusions: The results demonstrated that dyslipidemia MESHD was associated with the inflammatory response, disease severity and poor prognosis of COVID-19. High CRP/ HDL-C ratio may serve as an independently potential predictor for hospital mortality among patients with severe COVID-19.

    Prevalence SERO of malnutrition HP in COVID-19 inpatients: the Nutricov study

    Authors: Antoine Rouget; Fanny Vardon-Bounes; Pierre Lorber; Adrien Vavasseur; Olivier Marion; Bertrand Marcheix; Olivier Lairez; Laurent Balardy; Olivier Fourcade; Jean-Marie Conil; Vincent Minville

    doi:10.21203/rs.3.rs-41500/v1 Date: 2020-07-13 Source: ResearchSquare

    Background: Recent ESPEN guidelines highlighted the interest of prevention, diagnosis and treatment of malnutrition HP malnutrition MESHD in the management of coronavirus disease MESHD 19 (COVID-19) patients. The aim of our study was to evaluate the prevalence SERO of malnutrition HP malnutrition MESHD in patients hospitalized for COVID-19. Methods: Prospective observational cohort study on COVID-19 inpatients admitted to a tertiary hospital. Malnutrition HP Malnutrition MESHD was diagnosed according to the Global Leadership Initiative on Malnutrition HP two-step approach. Patients were divided in two groups according to the diagnosis of malnutrition HP malnutrition MESHD. Covariate selection for the multivariate analysis was based on P value <0.2 in univariate analysis, with a logistic regression model and a backward elimination procedure. A partitioning of the population was represented using a Classification and Regression Tree analysis.Results: 80 patients were prospectively enrolled in the study. Thirty patients (37.5%) had criteria for malnutrition HP malnutrition MESHD. The need for ICU admission (n=46, 57.5%) was similar in the two groups. Three patients who died (3.75%) were malnourished. Multivariate analysis exhibited that low BMI (OR=0.83, 95% CI [0.73-0.96], p=0.0083), dyslipidemia MESHD (OR=29.45, 95% CI [3.12-277.73], p=0.0031), oral intakes reduction <50% (OR=3.169, 95% CI [1.04-9.64], p=0.0422) and GFR (CKD-EPI) at admission (OR=0.979, 95% CI [0.96-0.998], p=0.0297) were associated with the occurrence of malnutrition HP malnutrition MESHD in COVID-19 inpatients.Conclusions: We demonstrate the existence of a high prevalence SERO of malnutrition HP malnutrition MESHD (37.5%) in a general cohort of COVID-19 inpatients according to GLIM criteria. Considering this high prevalence SERO, nutritional support in COVID-19 care seems an essential element. Trial registration: Ethical Committee No 2020-A01237-32)(RC31/20/0165 NUTRI-COV

    Causally Associations of Blood SERO Lipids Levels with COVID-19 Risk: Mendelian Randomization Study

    Authors: Kun Zhang; Yan Guo; Zhuo-Xin Wang; Jing-Miao Ding; Shi Yao; Hao Chen; Dong-Lin Zhu; Kun Zhang; Wei Huang; Shan-Shan Dong; Tie-Lin Yang

    doi:10.1101/2020.07.07.20147926 Date: 2020-07-07 Source: medRxiv

    Background: Coronavirus disease 2019 (COVID-19) is a global pandemic caused by the severe acute respiratory syndrome coronavirus 2 MESHD (SARS-Cov-2). It has been found that coronary artery disease MESHD ( CAD MESHD) is a comorbid condition for COVID-19. As the risk factors of CAD MESHD, whether blood SERO lipids levels are causally related to increasing susceptibility and severity of COVID-19 is still unknown. Design: We performed two-sample Mendelian Randomization (MR) analyses to explore whether dyslipidemia MESHD, low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol (HDL-c), triglyceride (TG) and total cholesterol (TC) were causally related to COVID-19 risk and severity. The GWAS summary data of blood SERO lipids involving in 188,578 individuals and dyslipidemia MESHD in a total of 53,991 individuals were used as exposures, respectively. Two COVID-19 GWASs including 1,221 infected patients and 1,610 severe patients defined as respiratory failure HP respiratory failure MESHD were employed as outcomes. Based on the MR estimates, we further carried out gene-based and gene-set analysis to explain the potential mechanism for causal effect. Results: The MR results showed that dyslipidemia MESHD was casually associated with the susceptibility of COVID-19 and induced 27% higher odds for COVID-19 infection MESHD (MR-IVW OR = 1.27, 95% CI: 1.08 to 1.49, p-value = 3.18 x 10-3). Moreover, the increasing level of blood SERO TC will raise 14 % higher odds for the susceptibility of COVID-19 (MR-IVW OR = 1.14, 95% CI: 1.04 to 1.25, p-value = 5.07 x 10-3). Gene-based analysis identified that ABO gene was associated with TC and the gene-set analysis found that immune processes were involved in the risk effect of TC. Conclusions: We obtained three conclusions: 1) Dyslipidemia MESHD is casually associated with the susceptibility of COVID-19; 2) TC is a risk factor for the susceptibility of COVID-19; 3) The different susceptibility of COVID-19 in specific blood SERO group may be partly explained by the TC concentration in diverse ABO blood SERO groups.

    COVID-19 Comorbidity and Metabolic Syndrome MESHD: Is There a Molecular Basis?

    Authors: Madhurima Basu; Chinmay Saha; Kamalika Roy Choudhury; Susmita Dutta; Sujoy Ghosh; Subhankar Chowdhury; Satinath Mukhopadhyay; Nitai P. Bhattacharyya

    id:10.20944/preprints202006.0245.v1 Date: 2020-06-21 Source: Preprints.org

    The risk factors associated with COVID-19 related severity, morbidity, and mortality, i.e., obesity HP obesity MESHD (often associated with NAFLD MESHD), hyperglycemia HP hyperglycemia MESHD, hypertension HP hypertension MESHD and dyslipidemia all cluster MESHD together as metabolic syndrome MESHD ( MetS MESHD). Instead of studying association of these risk factors with COVID-19, it makes sense studying the association between MetS MESHD on one hand and COVID-19 on the other. This study explores a molecular basis underpinning the above association. Severity of COVID-19 patients with MetS MESHD could be due to functional alterations of host proteins due to their interactions with viral proteins. We collected data from Enrichr (https://amp.pharm.mssm.edu/Enrichr/), DisGeNET (https://www.disgenet.org/) and others and carried out enrichment analysis using Enrichr. Various biological processes and pathways associated with viral protein interacting partners are known to involve in metabolic diseases MESHD. The molecular pathways underlying insulin resistance HP, insulin signaling and insulin secretion are not only involved in diabetes MESHD but also in CVD and obesity HP obesity MESHD (associated with non-alcoholic fatty liver disease MESHD; NAFLD MESHD). Lipid metabolism/lipogenesis, fatty acid oxidation and inflammation MESHD are associated with MetS MESHD. Viral interacting host proteins are associated and enriched with terms like hyperglycemia HP hyperglycemia MESHD, coronary artery disease MESHD, hypertensive disease MESHD related to CVD and liver diseases MESHD in DisGeNET. Association of viral interacting proteins with disease-relevant biological processes, pathways and disease-related terms suggests that altered host protein function following interaction with viral proteins might contribute to frequent occurrence and/or severity of COVID-19 in subjects with MetS MESHD. Such analysis not only provides a molecular basis of comorbidity but also incriminates host proteins in viral replication, growth and identifies possible drug targets for intervention.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.